Viewing the clinical trial protocol prior to submission and consulting with patients to ensure that it meets their needs and that the design is acceptable to them. Representatives from Bowel Research UK (and others) will sit on AMELIE committees to monitor clinical trial design and its progression.
Organising meetings to communicate results to different stakeholders using digital technology as well as traditional communication methods.
Engaging with the International Continence Society (ICS) and European Society of Coloproctology (ESCP) at annual meetings and via their websites to disseminate updates and results.
Consortium members will publicise activities of AMELIE when beneficiaries speak at events, such as national patient support meetings and international meetings covering regenerative medicine.
Devising a project specific website with dedicated patient and public pages reporting AMELIE’s research outcomes.
Announcing results and outstanding publications via the UCL press office, the AMELIE website and international news media.
AMELIE researchers will publish their original research findings in high profile journals, along with generating review articles, invited commentaries and editorials.
Consortium members will announce project results at national, international scientific and clinical meetings.
Trial results will be assimilated rapidly into expert guidance documents produced by stakeholder learned societies, notably the ICS and ESCP.
Investigating the existence of other EU funded grants within the same research field with the aim of forming a ‘cluster’ of incontinence research projects, for data sharing and the future development of co-created new innovation to accelerate the uptake of incontinence treatments.
Continuing to engage with regulatory authorities to ensure technology development in the AMELIE project aligns with regulatory requirements. Regulatory representatives will be invited to the annual General Assembly meeting to allow them to keep up to date with the project’s progress and assessing the long-term possibility of the new treatment being incorporated into existing treatment regimes.